After a tumultuous, two-year hiatus, FDA finally has a permanent director for the Office of Drug Safety. Gerald Dal Pan, MD, succeeded Victor Raczkowski, ending a drawn out serach for what is increasingly becoming a politically sensitive middle management job within FDA.
After a tumultuous, two-year hiatus, FDA finally has a permanent director for the Office of Drug Safety. On November 13, Gerald Dal Pan, MD, succeeded Victor Raczkowski, who left FDA for the private sector in 2003. The appointment ends a drawn out search for what is increasingly becoming a politically sensitive middle management job within FDA.
After a nationwide quest—and 23 qualified candidates—FDA ended up right back where it started. Dal Pan has been at FDA...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
